Can a pill boost brain blood flow in Alzheimer's? new trial aims to find out

NCT ID NCT07191821

ENROLLING_BY_INVITATION Disease control Sponsor: Imperial College London Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial tests whether an experimental drug called XBD173 can improve blood flow in the brains of people with Alzheimer's disease. About 51 participants will take the drug or a placebo for 28 days. Researchers will use MRI scans and blood tests to measure changes in brain blood flow and other markers.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: XBD173 (an experimental drug taken orally)
What this could lead to: If it works, this could point toward a new way to improve blood flow in the brain for people with Alzheimer's, potentially slowing memory decline.
What could go wrong: This is a small, early-phase trial testing a short-term effect on a biomarker (blood flow), not on memory or daily function. The drug may not show benefit or could have side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALZHEIMER'S DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Alzheimer disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ALZHEIMER'S DISEASE

Contacts and locations

Locations

NIHR Imperial CRF

London, W12 0HS, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.